Exploring the Future of Pruritus Treatment: 20+ Innovators Shaping the Therapeutic Pipeline | DelveInsight

The Pruritus market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Vanda Pharmaceuticals, Roche, Kamari Pharma Ltd., AB Science, Haisco Pharmaceuticals, and Mirum Pharmaceuticals. These industry pioneers are transforming treatment strategies and redefining the future of Pruritus, bringing new hope to patients worldwide.

DelveInsight's "Pruritus Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Pruritus market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Pruritus drugs, the Pruritus pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Pruritus Pipeline Report
• DelveInsight's Pruritus Pipeline analysis depicts a robust space with 20+ active players working to develop 25+ pipeline drugs for Pruritus treatment.
• The leading Pruritus companies include Vanda Pharmaceuticals, Roche, Kamari Pharma Ltd., AB Science, Haisco Pharmaceuticals, Mirum Pharmaceuticals, Incyte Corporation, GlaxoSmithKline, Shenyang Sunshine Pharmaceutical Co., Asana BioSciences, Galderma R&D, and others are evaluating their lead assets to improve the Pruritus treatment landscape.
• Key Pruritus pipeline therapies in various stages of development include Linerixibat, Nemolizumab, Dupilumab, Parentide, SHR 0410, ASN 008, Tradipitant, Abrocitinib, Nalbuphine extended release, Onabotulinum toxin A, LT 5001, BA 2101, and others.
• In December 2024, Galderma announced that the U.S. Food and Drug Administration (FDA) approved Nemluvio® (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients aged 12 and older. It is to be used alongside topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease isn't sufficiently controlled by topical prescription therapies.
• In October 2024, Mirum Pharmaceuticals (Nasdaq: MIRM) announced that the FDA granted Breakthrough Therapy Designation to volixibat as a potential treatment for cholestatic pruritus in patients with primary biliary cholangitis (PBC).
• In Sept 2024, Ipsen announced that the European Commission has granted approval for KAYFANDA (odevixibat) under exceptional circumstances to treat cholestatic pruritus in patients with Alagille Syndrome (ALGS) aged 6 months and older. Kayfanda is a once-daily, non-systemic ileal bile acid transport (IBAT) inhibitor. The active ingredient, odevixibat, works by blocking the ileal bile acid transporter, leading to a reduction in serum bile acids produced by the liver.
• In July 2024, the FDA expanded LIVMARLI's label to include treatment for cholestatic pruritus in infants aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC). This update also approves a higher concentration formula of Livmarli (maralixibat, Mirum Pharmaceuticals), previously approved only for patients aged 5 and older with pruritus and PFIC.

Request a sample and discover the recent breakthroughs happening in the Pruritus pipeline landscape @ https://www.delveinsight.com/report-store/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pruritus Overview
Pruritus, or itching, is a common symptom seen by dermatologists and primary care providers. Though often considered harmless, it can significantly impact a patient's quality of life and become debilitating when severe. While it frequently accompanies skin conditions, pruritus may also indicate underlying systemic diseases, making thorough evaluation essential.

Managing pruritus involves identifying triggers, assessing psychological impact, and implementing preventive strategies to ease discomfort. A detailed patient history-focused on the severity, duration, and environmental factors-is crucial, along with a physical exam to identify primary skin lesions or signs of scratching.

Itching is classified into four types: cutaneous (from skin inflammation), neuropathic (due to nerve damage, as in multiple sclerosis or shingles), neurogenic (central origin without nerve damage, like in cholestasis), and psychogenic (linked to mental health conditions such as delusional parasitosis).

Understanding the cause and classification of pruritus is key to effective diagnosis and targeted treatment.

Find out more about Pruritus medication @ https://www.delveinsight.com/report-store/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pruritus Treatment Analysis: Drug Profile
Tradipitant: Vanda Pharmaceuticals
Tradipitant is a neurokinin-1 (NK1) antagonist that blocks substance P, a molecule involved in itch signaling. Originally developed by Eli Lilly (as LY686017), it was acquired by Vanda Pharmaceuticals in 2012. The drug is currently in Phase III clinical trials for treating pruritus.

Vixarelimab: Roche
Vixarelimab is a fully human monoclonal antibody that targets OSMRβ, blocking the activity of IL-31 and oncostatin M (OSM)-two cytokines associated with itching, inflammation, and fibrosis. Developed by Kiniksa and now under Roche, it is in Phase II trials for pruritus, primarily in prurigo nodularis.

Key Pruritus Therapies and Companies
• Tradipitant: Vanda Pharmaceuticals
• Vixarelimab: Roche
• KM-001: Kamari Pharma Ltd.
• DUPIXENT: Sanofi
• CLE-400: Clexio Biosciences

Learn more about the novel and emerging Pruritus pipeline therapies @ https://www.delveinsight.com/report-store/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pruritus Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Pruritus Pipeline Report
• Coverage: Global
• Key Pruritus Companies: Vanda Pharmaceuticals, Roche, Kamari Pharma Ltd., AB Science, Haisco Pharmaceuticals, Mirum Pharmaceuticals, Incyte Corporation, GlaxoSmithKline, Shenyang Sunshine Pharmaceutical Co., Asana BioSciences, Galderma R&D, and others.
• Key Pruritus Pipeline Therapies: Linerixibat, Nemolizumab, Dupilumab, Parentide, SHR 0410, ASN 008, Tradipitant, Abrocitinib, Nalbuphine extended release, Onabotulinum toxin A, LT 5001, BA 2101, and others.

Dive deep into rich insights for drugs used for Pruritus treatment; visit @ https://www.delveinsight.com/report-store/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Pruritus Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Pruritus Pipeline Therapeutics
6. Pruritus Pipeline: Late-Stage Products (Phase III)
7. Pruritus Pipeline: Late-Stage Products (Phase III)
8. Pruritus Pipeline: Mid-Stage Products (Phase II)
9. Pruritus Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.